Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Rating of “Hold” by Analysts

Shares of Design Therapeutics, Inc. (NASDAQ:DSGNGet Free Report) have received an average rating of “Hold” from the six analysts that are currently covering the company, Marketbeat reports. Five research analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $6.60.

Several research analysts have issued reports on the stock. Piper Sandler upgraded shares of Design Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $6.00 to $12.00 in a research report on Tuesday. Wedbush restated a “neutral” rating and issued a $5.00 price target on shares of Design Therapeutics in a research report on Wednesday, March 20th. Finally, Royal Bank of Canada restated a “sector perform” rating and issued a $4.00 price target on shares of Design Therapeutics in a research report on Wednesday, March 20th.

Check Out Our Latest Report on Design Therapeutics

Insiders Place Their Bets

In other news, Director John P. Schmid acquired 17,809 shares of the stock in a transaction on Monday, March 25th. The shares were purchased at an average cost of $3.74 per share, for a total transaction of $66,605.66. Following the transaction, the director now owns 26,965 shares in the company, valued at approximately $100,849.10. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. In related news, Director John P. Schmid purchased 17,809 shares of the stock in a transaction dated Monday, March 25th. The shares were acquired at an average cost of $3.74 per share, for a total transaction of $66,605.66. Following the acquisition, the director now directly owns 26,965 shares in the company, valued at approximately $100,849.10. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director John P. Schmid purchased 9,156 shares of the stock in a transaction dated Friday, March 22nd. The shares were bought at an average price of $3.62 per share, for a total transaction of $33,144.72. Following the completion of the acquisition, the director now owns 9,156 shares in the company, valued at $33,144.72. The disclosure for this purchase can be found here. Corporate insiders own 25.70% of the company’s stock.

Hedge Funds Weigh In On Design Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. BML Capital Management LLC acquired a new stake in shares of Design Therapeutics in the 4th quarter valued at $2,728,000. Barclays PLC lifted its stake in shares of Design Therapeutics by 353.1% in the 3rd quarter. Barclays PLC now owns 71,678 shares of the company’s stock valued at $170,000 after purchasing an additional 55,858 shares during the last quarter. RTW Investments LP lifted its stake in shares of Design Therapeutics by 60.8% in the 3rd quarter. RTW Investments LP now owns 2,512,986 shares of the company’s stock valued at $5,931,000 after purchasing an additional 949,955 shares during the last quarter. Algert Global LLC lifted its stake in shares of Design Therapeutics by 83.3% in the 3rd quarter. Algert Global LLC now owns 35,620 shares of the company’s stock valued at $84,000 after purchasing an additional 16,190 shares during the last quarter. Finally, Jump Financial LLC lifted its stake in shares of Design Therapeutics by 284.7% in the 3rd quarter. Jump Financial LLC now owns 46,700 shares of the company’s stock valued at $110,000 after purchasing an additional 34,561 shares during the last quarter. 56.64% of the stock is currently owned by hedge funds and other institutional investors.

Design Therapeutics Price Performance

Shares of NASDAQ DSGN opened at $4.69 on Thursday. The firm’s 50-day moving average price is $3.44 and its two-hundred day moving average price is $2.76. Design Therapeutics has a 52-week low of $1.94 and a 52-week high of $8.47. The stock has a market capitalization of $264.94 million, a P/E ratio of -3.91 and a beta of 1.83.

Design Therapeutics (NASDAQ:DSGNGet Free Report) last posted its quarterly earnings results on Tuesday, March 19th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.11. As a group, equities research analysts expect that Design Therapeutics will post -1.26 earnings per share for the current year.

About Design Therapeutics

(Get Free Report

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.

Featured Articles

Analyst Recommendations for Design Therapeutics (NASDAQ:DSGN)

Receive News & Ratings for Design Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Design Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.